⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21325792 | 0.78 | — | — | |
| SCHEMBL17247575 | 0.77 | NPSR1 (0.36) | — | |
| SCHEMBL29956423 | 0.76 | ALDH1A1 (0.36) | — | |
| SCHEMBL2517185 | 0.76 | — | — | |
| SCHEMBL29950950 | 0.75 | NPC1 (0.49) | — | |
| SCHEMBL568038 | 0.74 | — | — | |
| SCHEMBL19212871 | 0.74 | — | — | |
| SCHEMBL19312691 | 0.74 | — | — | |
| SCHEMBL15277593 | 0.74 | — | — | |
| SCHEMBL4988200 | 0.74 | NPSR1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233768-B | Preparation method of 3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester | 徐州圣元化工有限公司 | 2021-08-03 | — | — | CN | claimed |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025044946-A1 | COMPOUND ACTING AS MRGPRX2 ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119504738-A | Compounds as MRGPRX2 antagonists, methods of preparation and use thereof | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| WO-2005000800-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-01-06 | — | — | WO | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |